Utilization, user characteristics, and adverse outcomes of insulin glargine originators and follow-on drug in patients with diabetes in the United States

BACKGROUND: The first follow-on drug (Basaglar) of the originator insulin glargine (Lantus), a long-acting insulin for treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM), was approved in 2015 in the United States. Information on the uptake, user characteristics, and outcomes of follow-on...

Descripción completa

Detalles Bibliográficos
Autores principales: Rai, Ashish, Nam, Young Hee, Mendelsohn, Aaron B, Marshall, James, McDermott, Cara L, Toh, Sengwee, Lockhart, Catherine M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387990/
https://www.ncbi.nlm.nih.gov/pubmed/37404073
http://dx.doi.org/10.18553/jmcp.2023.29.7.842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387990/
https://www.ncbi.nlm.nih.gov/pubmed/37404073
http://dx.doi.org/10.18553/jmcp.2023.29.7.842

Ejemplares similares